JAMA Internal Medicine: Pancreatic Cancer Topic Collection http://archinte.jamanetwork.com/ en-us Mon, 08 Apr 2013 00:00:00 GMT Mon, 08 Apr 2013 15:47:02 GMT Silverchair editor@archinte.jamanetwork.com webmaster@archinte.jamanetwork.com Glucagonlike Peptide 1–Based Drugs and Pancreatitis Clarity at Last, but What About Pancreatic Cancer? Comment on “Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus” GLP-1–Based Drugs and Pancreatitis http://archinte.jamanetwork.com/article.aspx?articleID=1660357 Mon, 08 Apr 2013 00:00:00 GMT Gier B, Butler PC. <span class="paragraphSection">The worldwide prevalence of type 2 diabetes mellitus (T2DM) is approaching 100 million. Most affected individuals are treated for decades. Not surprisingly, the market for drug treatment of T2DM is worth more than $20 billion per year. The most lucrative drugs are those still protected by patent and deemed worthy of selection despite high expense because of clear advantages over cheaper drugs no longer covered by patent protection.</span> 173 7 539 541 10.1001/jamainternmed.2013.3374 http://archinte.jamanetwork.com/article.aspx?articleID=1660357